Global Group A and Group C Meningococcal Polysaccharide Vaccine Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Page: 91

Published Date: 29 Jan 2024

Category: Pharma & Healthcare

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags

Description

According to our (Global Info Research) latest study, the global Group A and Group C Meningococcal Polysaccharide Vaccine market size was valued at USD 293.3 million in 2023 and is forecast to a readjusted size of USD 430.2 million by 2030 with a CAGR of 5.6% during review period.

After vaccination, the body can produce a humoral immune response. It is used to prevent infectious diseases caused by group A and group C meningococci, such as cerebrospinal meningitis and pneumonia.

Meningococcal disease, caused by Neisseria meningitidis, can cause serious illness and even death. The global burden of meningococcal disease, especially serogroups A and C, drives the need for effective vaccines to prevent these infections.

The Global Info Research report includes an overview of the development of the Group A and Group C Meningococcal Polysaccharide Vaccine industry chain, the market status of Hospital (Class 1 Vaccine, Class II Vaccine), Clinic (Class 1 Vaccine, Class II Vaccine), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Group A and Group C Meningococcal Polysaccharide Vaccine.

Regionally, the report analyzes the Group A and Group C Meningococcal Polysaccharide Vaccine markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Group A and Group C Meningococcal Polysaccharide Vaccine market, with robust domestic demand, supportive policies, and a strong manufacturing base.

Key Features:
The report presents comprehensive understanding of the Group A and Group C Meningococcal Polysaccharide Vaccine market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Group A and Group C Meningococcal Polysaccharide Vaccine industry.

The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Units), revenue generated, and market share of different by Type (e.g., Class 1 Vaccine, Class II Vaccine).

Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Group A and Group C Meningococcal Polysaccharide Vaccine market.

Regional Analysis: The report involves examining the Group A and Group C Meningococcal Polysaccharide Vaccine market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.

Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Group A and Group C Meningococcal Polysaccharide Vaccine market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.

The report also involves a more granular approach to Group A and Group C Meningococcal Polysaccharide Vaccine:
Company Analysis: Report covers individual Group A and Group C Meningococcal Polysaccharide Vaccine manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.

Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Group A and Group C Meningococcal Polysaccharide Vaccine This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospital, Clinic).

Technology Analysis: Report covers specific technologies relevant to Group A and Group C Meningococcal Polysaccharide Vaccine. It assesses the current state, advancements, and potential future developments in Group A and Group C Meningococcal Polysaccharide Vaccine areas.

Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Group A and Group C Meningococcal Polysaccharide Vaccine market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.

Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.

Market Segmentation
Group A and Group C Meningococcal Polysaccharide Vaccine market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.

Market segment by Type
    Class 1 Vaccine
    Class II Vaccine

Market segment by Application
    Hospital
    Clinic

Major players covered
    Walvax
    Lanzhou Institute of Biological Products
    AIM Bio
    Sanofi Pasteur
    GSK
    Hualan Bio
    ZFSW
    Changsheng
    Kanghua Bio

Market segment by region, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Group A and Group C Meningococcal Polysaccharide Vaccine product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Group A and Group C Meningococcal Polysaccharide Vaccine, with price, sales, revenue and global market share of Group A and Group C Meningococcal Polysaccharide Vaccine from 2019 to 2024.
Chapter 3, the Group A and Group C Meningococcal Polysaccharide Vaccine competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Group A and Group C Meningococcal Polysaccharide Vaccine breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023.and Group A and Group C Meningococcal Polysaccharide Vaccine market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Group A and Group C Meningococcal Polysaccharide Vaccine.
Chapter 14 and 15, to describe Group A and Group C Meningococcal Polysaccharide Vaccine sales channel, distributors, customers, research findings and conclusion.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope of Group A and Group C Meningococcal Polysaccharide Vaccine
    1.2 Market Estimation Caveats and Base Year
    1.3 Market Analysis by Type
        1.3.1 Overview: Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Type: 2019 Versus 2023 Versus 2030
        1.3.2 Class 1 Vaccine
        1.3.3 Class II Vaccine
    1.4 Market Analysis by Application
        1.4.1 Overview: Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Application: 2019 Versus 2023 Versus 2030
        1.4.2 Hospital
        1.4.3 Clinic
    1.5 Global Group A and Group C Meningococcal Polysaccharide Vaccine Market Size & Forecast
        1.5.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value (2019 & 2023 & 2030)
        1.5.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity (2019-2030)
        1.5.3 Global Group A and Group C Meningococcal Polysaccharide Vaccine Average Price (2019-2030)

2 Manufacturers Profiles
    2.1 Walvax
        2.1.1 Walvax Details
        2.1.2 Walvax Major Business
        2.1.3 Walvax Group A and Group C Meningococcal Polysaccharide Vaccine Product and Services
        2.1.4 Walvax Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.1.5 Walvax Recent Developments/Updates
    2.2 Lanzhou Institute of Biological Products
        2.2.1 Lanzhou Institute of Biological Products Details
        2.2.2 Lanzhou Institute of Biological Products Major Business
        2.2.3 Lanzhou Institute of Biological Products Group A and Group C Meningococcal Polysaccharide Vaccine Product and Services
        2.2.4 Lanzhou Institute of Biological Products Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.2.5 Lanzhou Institute of Biological Products Recent Developments/Updates
    2.3 AIM Bio
        2.3.1 AIM Bio Details
        2.3.2 AIM Bio Major Business
        2.3.3 AIM Bio Group A and Group C Meningococcal Polysaccharide Vaccine Product and Services
        2.3.4 AIM Bio Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.3.5 AIM Bio Recent Developments/Updates
    2.4 Sanofi Pasteur
        2.4.1 Sanofi Pasteur Details
        2.4.2 Sanofi Pasteur Major Business
        2.4.3 Sanofi Pasteur Group A and Group C Meningococcal Polysaccharide Vaccine Product and Services
        2.4.4 Sanofi Pasteur Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.4.5 Sanofi Pasteur Recent Developments/Updates
    2.5 GSK
        2.5.1 GSK Details
        2.5.2 GSK Major Business
        2.5.3 GSK Group A and Group C Meningococcal Polysaccharide Vaccine Product and Services
        2.5.4 GSK Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.5.5 GSK Recent Developments/Updates
    2.6 Hualan Bio
        2.6.1 Hualan Bio Details
        2.6.2 Hualan Bio Major Business
        2.6.3 Hualan Bio Group A and Group C Meningococcal Polysaccharide Vaccine Product and Services
        2.6.4 Hualan Bio Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.6.5 Hualan Bio Recent Developments/Updates
    2.7 ZFSW
        2.7.1 ZFSW Details
        2.7.2 ZFSW Major Business
        2.7.3 ZFSW Group A and Group C Meningococcal Polysaccharide Vaccine Product and Services
        2.7.4 ZFSW Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.7.5 ZFSW Recent Developments/Updates
    2.8 Changsheng
        2.8.1 Changsheng Details
        2.8.2 Changsheng Major Business
        2.8.3 Changsheng Group A and Group C Meningococcal Polysaccharide Vaccine Product and Services
        2.8.4 Changsheng Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.8.5 Changsheng Recent Developments/Updates
    2.9 Kanghua Bio
        2.9.1 Kanghua Bio Details
        2.9.2 Kanghua Bio Major Business
        2.9.3 Kanghua Bio Group A and Group C Meningococcal Polysaccharide Vaccine Product and Services
        2.9.4 Kanghua Bio Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.9.5 Kanghua Bio Recent Developments/Updates

3 Competitive Environment: Group A and Group C Meningococcal Polysaccharide Vaccine by Manufacturer
    3.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Manufacturer (2019-2024)
    3.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Manufacturer (2019-2024)
    3.3 Global Group A and Group C Meningococcal Polysaccharide Vaccine Average Price by Manufacturer (2019-2024)
    3.4 Market Share Analysis (2023)
        3.4.1 Producer Shipments of Group A and Group C Meningococcal Polysaccharide Vaccine by Manufacturer Revenue ($MM) and Market Share (%): 2023
        3.4.2 Top 3 Group A and Group C Meningococcal Polysaccharide Vaccine Manufacturer Market Share in 2023
        3.4.2 Top 6 Group A and Group C Meningococcal Polysaccharide Vaccine Manufacturer Market Share in 2023
    3.5 Group A and Group C Meningococcal Polysaccharide Vaccine Market: Overall Company Footprint Analysis
        3.5.1 Group A and Group C Meningococcal Polysaccharide Vaccine Market: Region Footprint
        3.5.2 Group A and Group C Meningococcal Polysaccharide Vaccine Market: Company Product Type Footprint
        3.5.3 Group A and Group C Meningococcal Polysaccharide Vaccine Market: Company Product Application Footprint
    3.6 New Market Entrants and Barriers to Market Entry
    3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region
    4.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Market Size by Region
        4.1.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Region (2019-2030)
        4.1.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Region (2019-2030)
        4.1.3 Global Group A and Group C Meningococcal Polysaccharide Vaccine Average Price by Region (2019-2030)
    4.2 North America Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value (2019-2030)
    4.3 Europe Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value (2019-2030)
    4.4 Asia-Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value (2019-2030)
    4.5 South America Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value (2019-2030)
    4.6 Middle East and Africa Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value (2019-2030)

5 Market Segment by Type
    5.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Type (2019-2030)
    5.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Type (2019-2030)
    5.3 Global Group A and Group C Meningococcal Polysaccharide Vaccine Average Price by Type (2019-2030)

6 Market Segment by Application
    6.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Application (2019-2030)
    6.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Application (2019-2030)
    6.3 Global Group A and Group C Meningococcal Polysaccharide Vaccine Average Price by Application (2019-2030)

7 North America
    7.1 North America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Type (2019-2030)
    7.2 North America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Application (2019-2030)
    7.3 North America Group A and Group C Meningococcal Polysaccharide Vaccine Market Size by Country
        7.3.1 North America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Country (2019-2030)
        7.3.2 North America Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Country (2019-2030)
        7.3.3 United States Market Size and Forecast (2019-2030)
        7.3.4 Canada Market Size and Forecast (2019-2030)
        7.3.5 Mexico Market Size and Forecast (2019-2030)

8 Europe
    8.1 Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Type (2019-2030)
    8.2 Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Application (2019-2030)
    8.3 Europe Group A and Group C Meningococcal Polysaccharide Vaccine Market Size by Country
        8.3.1 Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Country (2019-2030)
        8.3.2 Europe Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Country (2019-2030)
        8.3.3 Germany Market Size and Forecast (2019-2030)
        8.3.4 France Market Size and Forecast (2019-2030)
        8.3.5 United Kingdom Market Size and Forecast (2019-2030)
        8.3.6 Russia Market Size and Forecast (2019-2030)
        8.3.7 Italy Market Size and Forecast (2019-2030)

9 Asia-Pacific
    9.1 Asia-Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Type (2019-2030)
    9.2 Asia-Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Application (2019-2030)
    9.3 Asia-Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Market Size by Region
        9.3.1 Asia-Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Region (2019-2030)
        9.3.2 Asia-Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Region (2019-2030)
        9.3.3 China Market Size and Forecast (2019-2030)
        9.3.4 Japan Market Size and Forecast (2019-2030)
        9.3.5 Korea Market Size and Forecast (2019-2030)
        9.3.6 India Market Size and Forecast (2019-2030)
        9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
        9.3.8 Australia Market Size and Forecast (2019-2030)

10 South America
    10.1 South America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Type (2019-2030)
    10.2 South America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Application (2019-2030)
    10.3 South America Group A and Group C Meningococcal Polysaccharide Vaccine Market Size by Country
        10.3.1 South America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Country (2019-2030)
        10.3.2 South America Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Country (2019-2030)
        10.3.3 Brazil Market Size and Forecast (2019-2030)
        10.3.4 Argentina Market Size and Forecast (2019-2030)

11 Middle East & Africa
    11.1 Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Type (2019-2030)
    11.2 Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Application (2019-2030)
    11.3 Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Market Size by Country
        11.3.1 Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Country (2019-2030)
        11.3.2 Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Country (2019-2030)
        11.3.3 Turkey Market Size and Forecast (2019-2030)
        11.3.4 Egypt Market Size and Forecast (2019-2030)
        11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
        11.3.6 South Africa Market Size and Forecast (2019-2030)

12 Market Dynamics
    12.1 Group A and Group C Meningococcal Polysaccharide Vaccine Market Drivers
    12.2 Group A and Group C Meningococcal Polysaccharide Vaccine Market Restraints
    12.3 Group A and Group C Meningococcal Polysaccharide Vaccine Trends Analysis
    12.4 Porters Five Forces Analysis
        12.4.1 Threat of New Entrants
        12.4.2 Bargaining Power of Suppliers
        12.4.3 Bargaining Power of Buyers
        12.4.4 Threat of Substitutes
        12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain
    13.1 Raw Material of Group A and Group C Meningococcal Polysaccharide Vaccine and Key Manufacturers
    13.2 Manufacturing Costs Percentage of Group A and Group C Meningococcal Polysaccharide Vaccine
    13.3 Group A and Group C Meningococcal Polysaccharide Vaccine Production Process
    13.4 Group A and Group C Meningococcal Polysaccharide Vaccine Industrial Chain

14 Shipments by Distribution Channel
    14.1 Sales Channel
        14.1.1 Direct to End-User
        14.1.2 Distributors
    14.2 Group A and Group C Meningococcal Polysaccharide Vaccine Typical Distributors
    14.3 Group A and Group C Meningococcal Polysaccharide Vaccine Typical Customers

15 Research Findings and Conclusion

16 Appendix
    16.1 Methodology
    16.2 Research Process and Data Source
    16.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
    Table 2. Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
    Table 3. Walvax Basic Information, Manufacturing Base and Competitors
    Table 4. Walvax Major Business
    Table 5. Walvax Group A and Group C Meningococcal Polysaccharide Vaccine Product and Services
    Table 6. Walvax Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 7. Walvax Recent Developments/Updates
    Table 8. Lanzhou Institute of Biological Products Basic Information, Manufacturing Base and Competitors
    Table 9. Lanzhou Institute of Biological Products Major Business
    Table 10. Lanzhou Institute of Biological Products Group A and Group C Meningococcal Polysaccharide Vaccine Product and Services
    Table 11. Lanzhou Institute of Biological Products Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 12. Lanzhou Institute of Biological Products Recent Developments/Updates
    Table 13. AIM Bio Basic Information, Manufacturing Base and Competitors
    Table 14. AIM Bio Major Business
    Table 15. AIM Bio Group A and Group C Meningococcal Polysaccharide Vaccine Product and Services
    Table 16. AIM Bio Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 17. AIM Bio Recent Developments/Updates
    Table 18. Sanofi Pasteur Basic Information, Manufacturing Base and Competitors
    Table 19. Sanofi Pasteur Major Business
    Table 20. Sanofi Pasteur Group A and Group C Meningococcal Polysaccharide Vaccine Product and Services
    Table 21. Sanofi Pasteur Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 22. Sanofi Pasteur Recent Developments/Updates
    Table 23. GSK Basic Information, Manufacturing Base and Competitors
    Table 24. GSK Major Business
    Table 25. GSK Group A and Group C Meningococcal Polysaccharide Vaccine Product and Services
    Table 26. GSK Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 27. GSK Recent Developments/Updates
    Table 28. Hualan Bio Basic Information, Manufacturing Base and Competitors
    Table 29. Hualan Bio Major Business
    Table 30. Hualan Bio Group A and Group C Meningococcal Polysaccharide Vaccine Product and Services
    Table 31. Hualan Bio Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 32. Hualan Bio Recent Developments/Updates
    Table 33. ZFSW Basic Information, Manufacturing Base and Competitors
    Table 34. ZFSW Major Business
    Table 35. ZFSW Group A and Group C Meningococcal Polysaccharide Vaccine Product and Services
    Table 36. ZFSW Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 37. ZFSW Recent Developments/Updates
    Table 38. Changsheng Basic Information, Manufacturing Base and Competitors
    Table 39. Changsheng Major Business
    Table 40. Changsheng Group A and Group C Meningococcal Polysaccharide Vaccine Product and Services
    Table 41. Changsheng Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 42. Changsheng Recent Developments/Updates
    Table 43. Kanghua Bio Basic Information, Manufacturing Base and Competitors
    Table 44. Kanghua Bio Major Business
    Table 45. Kanghua Bio Group A and Group C Meningococcal Polysaccharide Vaccine Product and Services
    Table 46. Kanghua Bio Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 47. Kanghua Bio Recent Developments/Updates
    Table 48. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Manufacturer (2019-2024) & (K Units)
    Table 49. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Manufacturer (2019-2024) & (USD Million)
    Table 50. Global Group A and Group C Meningococcal Polysaccharide Vaccine Average Price by Manufacturer (2019-2024) & (US$/Unit)
    Table 51. Market Position of Manufacturers in Group A and Group C Meningococcal Polysaccharide Vaccine, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2023
    Table 52. Head Office and Group A and Group C Meningococcal Polysaccharide Vaccine Production Site of Key Manufacturer
    Table 53. Group A and Group C Meningococcal Polysaccharide Vaccine Market: Company Product Type Footprint
    Table 54. Group A and Group C Meningococcal Polysaccharide Vaccine Market: Company Product Application Footprint
    Table 55. Group A and Group C Meningococcal Polysaccharide Vaccine New Market Entrants and Barriers to Market Entry
    Table 56. Group A and Group C Meningococcal Polysaccharide Vaccine Mergers, Acquisition, Agreements, and Collaborations
    Table 57. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Region (2019-2024) & (K Units)
    Table 58. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Region (2025-2030) & (K Units)
    Table 59. Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Region (2019-2024) & (USD Million)
    Table 60. Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Region (2025-2030) & (USD Million)
    Table 61. Global Group A and Group C Meningococcal Polysaccharide Vaccine Average Price by Region (2019-2024) & (US$/Unit)
    Table 62. Global Group A and Group C Meningococcal Polysaccharide Vaccine Average Price by Region (2025-2030) & (US$/Unit)
    Table 63. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Type (2019-2024) & (K Units)
    Table 64. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Type (2025-2030) & (K Units)
    Table 65. Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Type (2019-2024) & (USD Million)
    Table 66. Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Type (2025-2030) & (USD Million)
    Table 67. Global Group A and Group C Meningococcal Polysaccharide Vaccine Average Price by Type (2019-2024) & (US$/Unit)
    Table 68. Global Group A and Group C Meningococcal Polysaccharide Vaccine Average Price by Type (2025-2030) & (US$/Unit)
    Table 69. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Application (2019-2024) & (K Units)
    Table 70. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Application (2025-2030) & (K Units)
    Table 71. Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Application (2019-2024) & (USD Million)
    Table 72. Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Application (2025-2030) & (USD Million)
    Table 73. Global Group A and Group C Meningococcal Polysaccharide Vaccine Average Price by Application (2019-2024) & (US$/Unit)
    Table 74. Global Group A and Group C Meningococcal Polysaccharide Vaccine Average Price by Application (2025-2030) & (US$/Unit)
    Table 75. North America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Type (2019-2024) & (K Units)
    Table 76. North America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Type (2025-2030) & (K Units)
    Table 77. North America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Application (2019-2024) & (K Units)
    Table 78. North America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Application (2025-2030) & (K Units)
    Table 79. North America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Country (2019-2024) & (K Units)
    Table 80. North America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Country (2025-2030) & (K Units)
    Table 81. North America Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Country (2019-2024) & (USD Million)
    Table 82. North America Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Country (2025-2030) & (USD Million)
    Table 83. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Type (2019-2024) & (K Units)
    Table 84. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Type (2025-2030) & (K Units)
    Table 85. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Application (2019-2024) & (K Units)
    Table 86. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Application (2025-2030) & (K Units)
    Table 87. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Country (2019-2024) & (K Units)
    Table 88. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Country (2025-2030) & (K Units)
    Table 89. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Country (2019-2024) & (USD Million)
    Table 90. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Country (2025-2030) & (USD Million)
    Table 91. Asia-Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Type (2019-2024) & (K Units)
    Table 92. Asia-Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Type (2025-2030) & (K Units)
    Table 93. Asia-Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Application (2019-2024) & (K Units)
    Table 94. Asia-Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Application (2025-2030) & (K Units)
    Table 95. Asia-Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Region (2019-2024) & (K Units)
    Table 96. Asia-Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Region (2025-2030) & (K Units)
    Table 97. Asia-Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Region (2019-2024) & (USD Million)
    Table 98. Asia-Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Region (2025-2030) & (USD Million)
    Table 99. South America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Type (2019-2024) & (K Units)
    Table 100. South America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Type (2025-2030) & (K Units)
    Table 101. South America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Application (2019-2024) & (K Units)
    Table 102. South America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Application (2025-2030) & (K Units)
    Table 103. South America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Country (2019-2024) & (K Units)
    Table 104. South America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Country (2025-2030) & (K Units)
    Table 105. South America Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Country (2019-2024) & (USD Million)
    Table 106. South America Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Country (2025-2030) & (USD Million)
    Table 107. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Type (2019-2024) & (K Units)
    Table 108. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Type (2025-2030) & (K Units)
    Table 109. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Application (2019-2024) & (K Units)
    Table 110. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Application (2025-2030) & (K Units)
    Table 111. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Region (2019-2024) & (K Units)
    Table 112. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Region (2025-2030) & (K Units)
    Table 113. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Region (2019-2024) & (USD Million)
    Table 114. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Region (2025-2030) & (USD Million)
    Table 115. Group A and Group C Meningococcal Polysaccharide Vaccine Raw Material
    Table 116. Key Manufacturers of Group A and Group C Meningococcal Polysaccharide Vaccine Raw Materials
    Table 117. Group A and Group C Meningococcal Polysaccharide Vaccine Typical Distributors
    Table 118. Group A and Group C Meningococcal Polysaccharide Vaccine Typical Customers
List of Figures
    Figure 1. Group A and Group C Meningococcal Polysaccharide Vaccine Picture
    Figure 2. Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
    Figure 3. Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value Market Share by Type in 2023
    Figure 4. Class 1 Vaccine Examples
    Figure 5. Class II Vaccine Examples
    Figure 6. Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
    Figure 7. Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value Market Share by Application in 2023
    Figure 8. Hospital Examples
    Figure 9. Clinic Examples
    Figure 10. Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value, (USD Million): 2019 & 2023 & 2030
    Figure 11. Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Forecast (2019-2030) & (USD Million)
    Figure 12. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity (2019-2030) & (K Units)
    Figure 13. Global Group A and Group C Meningococcal Polysaccharide Vaccine Average Price (2019-2030) & (US$/Unit)
    Figure 14. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity Market Share by Manufacturer in 2023
    Figure 15. Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value Market Share by Manufacturer in 2023
    Figure 16. Producer Shipments of Group A and Group C Meningococcal Polysaccharide Vaccine by Manufacturer Sales Quantity ($MM) and Market Share (%): 2023
    Figure 17. Top 3 Group A and Group C Meningococcal Polysaccharide Vaccine Manufacturer (Consumption Value) Market Share in 2023
    Figure 18. Top 6 Group A and Group C Meningococcal Polysaccharide Vaccine Manufacturer (Consumption Value) Market Share in 2023
    Figure 19. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity Market Share by Region (2019-2030)
    Figure 20. Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value Market Share by Region (2019-2030)
    Figure 21. North America Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value (2019-2030) & (USD Million)
    Figure 22. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value (2019-2030) & (USD Million)
    Figure 23. Asia-Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value (2019-2030) & (USD Million)
    Figure 24. South America Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value (2019-2030) & (USD Million)
    Figure 25. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value (2019-2030) & (USD Million)
    Figure 26. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity Market Share by Type (2019-2030)
    Figure 27. Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value Market Share by Type (2019-2030)
    Figure 28. Global Group A and Group C Meningococcal Polysaccharide Vaccine Average Price by Type (2019-2030) & (US$/Unit)
    Figure 29. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity Market Share by Application (2019-2030)
    Figure 30. Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value Market Share by Application (2019-2030)
    Figure 31. Global Group A and Group C Meningococcal Polysaccharide Vaccine Average Price by Application (2019-2030) & (US$/Unit)
    Figure 32. North America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity Market Share by Type (2019-2030)
    Figure 33. North America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity Market Share by Application (2019-2030)
    Figure 34. North America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity Market Share by Country (2019-2030)
    Figure 35. North America Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value Market Share by Country (2019-2030)
    Figure 36. United States Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 37. Canada Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 38. Mexico Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 39. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity Market Share by Type (2019-2030)
    Figure 40. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity Market Share by Application (2019-2030)
    Figure 41. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity Market Share by Country (2019-2030)
    Figure 42. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value Market Share by Country (2019-2030)
    Figure 43. Germany Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 44. France Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 45. United Kingdom Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 46. Russia Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 47. Italy Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 48. Asia-Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity Market Share by Type (2019-2030)
    Figure 49. Asia-Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity Market Share by Application (2019-2030)
    Figure 50. Asia-Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity Market Share by Region (2019-2030)
    Figure 51. Asia-Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value Market Share by Region (2019-2030)
    Figure 52. China Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 53. Japan Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 54. Korea Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 55. India Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 56. Southeast Asia Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 57. Australia Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 58. South America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity Market Share by Type (2019-2030)
    Figure 59. South America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity Market Share by Application (2019-2030)
    Figure 60. South America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity Market Share by Country (2019-2030)
    Figure 61. South America Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value Market Share by Country (2019-2030)
    Figure 62. Brazil Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 63. Argentina Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 64. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity Market Share by Type (2019-2030)
    Figure 65. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity Market Share by Application (2019-2030)
    Figure 66. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity Market Share by Region (2019-2030)
    Figure 67. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value Market Share by Region (2019-2030)
    Figure 68. Turkey Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 69. Egypt Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 70. Saudi Arabia Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 71. South Africa Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 72. Group A and Group C Meningococcal Polysaccharide Vaccine Market Drivers
    Figure 73. Group A and Group C Meningococcal Polysaccharide Vaccine Market Restraints
    Figure 74. Group A and Group C Meningococcal Polysaccharide Vaccine Market Trends
    Figure 75. Porters Five Forces Analysis
    Figure 76. Manufacturing Cost Structure Analysis of Group A and Group C Meningococcal Polysaccharide Vaccine in 2023
    Figure 77. Manufacturing Process Analysis of Group A and Group C Meningococcal Polysaccharide Vaccine
    Figure 78. Group A and Group C Meningococcal Polysaccharide Vaccine Industrial Chain
    Figure 79. Sales Quantity Channel: Direct to End-User vs Distributors
    Figure 80. Direct Channel Pros & Cons
    Figure 81. Indirect Channel Pros & Cons
    Figure 82. Methodology
    Figure 83. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Companies Mentioned

Walvax
Lanzhou Institute of Biological Products
AIM Bio
Sanofi Pasteur
GSK
Hualan Bio
ZFSW
Changsheng
Kanghua Bio

Related Reports

Global Group A and Group C Meningococcal Polysaccharide Vaccine Supply, Demand and Key Producers, 2024-2030

Global Group A and Group C Meningococcal Polysaccharide Vaccine Supply, Demand and Key Producers, 2024-2030

date 02 Mar 2024

date Pharma & Healthcare

The global Group A and Group C Meningococcal Polysaccharide Vaccine market size is expected to reach $ 430.2 million by 2030, rising at a market growth of 5.6% CAGR during the forecast period (2024-2030).

Product Tags

Group A and Group C Meningococcal Polysaccharide Vaccine

GABA Supplements

L-carnitine Capsule

Opical Thrombin

Purchase Options

Single User License

USD3480.00

Multi User License

USD5220.00

Corporate Users License

USD6960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>